Reaction
Faecal Calprotectin Abnormal reporting signals
As of the last recalculation, Faecal Calprotectin Abnormal appears in 402 FAERS reports alongside 11 co-occurring drug terms. The strongest observed disproportionality signal is ADALIMUMAB-ADAZ (PRR 84.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Adalimumab-Adaz | 71 | 84.4 | 84.5 |
| Adalimumab-Fkjp | 59 | 77.1 | 77.2 |
| Adalimumab-Aaty | 59 | 75.5 | 75.6 |
| Infliximab-Dyyb | 28 | 53.2 | 53.3 |
| Naltrexone Hydrochloride And Bupropion Hydrochloride | 8 | 49.5 | 49.6 |
| Mesalamine | 35 | 35.2 | 35.3 |
| Vedolizumab | 51 | 35.0 | 35.0 |
| Mercaptopurine | 11 | 33.7 | 33.8 |
| Tofacitinib Citrate | 8 | 32.2 | 32.2 |
| Ustekinumab | 47 | 26.8 | 26.8 |
| Risankizumab-Rzaa | 33 | 22.7 | 22.7 |